Morgan Stanley lowers Shenzhen Hepalink's target price to Rmb8.30 and maintains an Underweight view

Overview

Morgan Stanley released a risk-reward update on Shenzhen Hepalink Pharmaceutical. The report notes that the company is a global leading supplier of heparin API and is extending downstream into higher-margin enoxaparin formulations; however, post-pandemic heparin API exports have declined and remained volatile, and although formulations and CDMO now account for a larger share of revenue and partly offset margin pressure, the overall valuation is still viewed as expensive.

Core views

The core view is cautious: the report maintains an Underweight rating, arguing that Hepalink's A-shares at about 20x forward P/E are unattractive relative to approximately 15% earnings CAGR in 2026-28e; even in the most optimistic scenario, valuation is only expected to revert to the API industry average, corresponding to 21.0x 2026e P/E and a bull-case value of Rmb12.20. The base-case target price is Rmb8.30, and the bear-case value is Rmb5.60.

Analysis framework

The report evaluates risk-reward using the Morgan Stanley ModelWare framework, scenario valuation, and segment revenue assumptions. Valuation assumptions include an 8.8% cost of equity, 4.0% terminal growth rate, an 80/20 steady-state equity/debt structure, and 2026e P/E as the main reference for bull, base, and bear scenarios.

Methodology notes

• Valuation frameworkMorgan Stanley ModelWare

  Model-based valuation and scenario analysis

  The report states that, unless otherwise noted, relevant metrics are based on the Morgan Stanley ModelWare framework.

• Discounting assumptionsDCF assumptions

  Cost of equity, terminal growth, and capital structure

  The report assumes an 8.8% cost of equity, a 4.0% terminal growth rate, and an 80/20 steady-state equity/debt structure.

• Relative valuationP/E scenario analysis

  2026e P/E scenario valuation

  The bull-case scenario uses 21.0x 2026e P/E, the base-case scenario uses 14.8x 2026e P/E, and the bear-case scenario uses 9.5x 2026e P/E.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Shenzhen Hepalink Pharmaceutical (002399.SZ)

  Covered company stock

  Strengths

  A globally leading heparin API supplier, extending into higher-margin enoxaparin formulations, with rising contributions from formulations and CDMO revenue that can partly offset gross margin decline.

  Weaknesses

  Post-pandemic heparin API exports have declined and remained volatile, and the report views both pricing power and the long-term growth theme negatively.

  Comparison

  The report believes the A-share valuation of about 20x forward P/E is expensive relative to about 15% earnings CAGR in 2026-28e; even in the most optimistic case, P/E only reverts to the API industry average of 21x.

  Risks

  API prices, raw material costs, export demand, domestic competition, generic competition, and CDMO outsourcing demand could all affect the target price and rating.

Key data

• RatingUnderweightThe stock's total return is expected to underperform the average of the analyst's industry coverage over the next 12-18 months.
• Target price revisionRmb8.60 -> Rmb8.30The target price is lowered by about 3%, reflecting lower revenue assumptions after 2025 results.
• Current share priceRmb11.35Closing price as of 2026-04-16.
• Implied upside/downside-26.87%Based on the Rmb8.30 target price and the current share price of Rmb11.35.
• Bull-case scenarioRmb12.20Corresponds to 21.0x 2026e P/E, about +7.49% versus the current price.
• Bear-case scenarioRmb5.60Corresponds to 9.5x 2026e P/E, about -50.66% versus the current price.
• 2026e EPSRmb0.56Previous forecast was Rmb0.59.
• 2027e EPSRmb0.67Previous forecast was Rmb0.69.
• 2028e EPSRmb0.74Previous forecast was Rmb0.76.
• 2026-28e segment revenue CAGRFormulations 8%, API 2%, CDMO 4%Corresponds to segment revenue growth assumptions under the report's base-case scenario.
• Institutional active ownership13.7%Inst. Owners, % Active as disclosed in the report.

Impact & implications

The cuts to earnings forecasts and target price reinforce the report's cautious conclusion: even though the company has structural improvement from expansion in downstream formulations and CDMO businesses, volatility in heparin API export demand, fluctuations in raw material and product prices, and elevated valuation still constrain the stock's risk-reward. For investors, the key debates are whether API prices will rebound, whether formulations can gain market share, whether CDMO demand will recover, and whether the A-share valuation can absorb lower growth expectations.

Risks

• Heparin API export demand continues to fluctuate or decline.
• Crude heparin or pig small intestine mucosa prices remain high, compressing API gross margin.
• API shipment share is materially taken by domestic competitors.
• Enoxaparin formulations face pressure from generic entry and substitution.
• Outsourcing demand for biologics CDMO slows.
• Downstream customers do not fully benefit from lower hog prices or raw material prices, resulting in less-than-expected margin improvement.

What to watch

• Whether 2026-28e revenue and core earnings can recover from the low base in 2025.
• Whether heparin API prices rise suddenly or raw material prices fall further.
• Changes in market share in Europe and the United States formulations markets.
• CDMO share gains in cell therapy and monoclonal antibodies.
• Whether Chinese peers without U.S. manufacturing bases cede market share.
• Whether A-share forward P/E reverts from about 20x toward the API industry average.